Phase 2 study of camrelizumab plus famitinib for advanced/metastatic urothelial carcinoma after platinum-based therapy

Blockade of an immune checkpoint in combination with antiangiogenesis is an effective strategy for multiple cancers. A multicenter phase 2 basket study in China evaluates the combination of camrelizumab and famitinib in eight cohorts of genitourinary or gynecological cancers. In the cohort of patients with advanced or metastatic urothelial carcinoma and progression within 12 months after completion of platinum-based chemotherapy, the combination had potent antitumor activity, especially in the subpopulation of patients with bladder cancer.